Future Live Meetings
Second Annual Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Philadelphia, PA
Date: September 26, 2009
Click Here For More Information
|
Current Online Activities
The rationale for personalized therapies for lung cancer and head & neck cancer
Roy S. Herbst, MD, PhD
Session 1a from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 16:48
Click Here For More Information
The role of gene signatures in the prognosis of personalizing therapies for lung cancer
Joseph R. Nevins, PhD
Session 2a from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 18:20
Click Here For More Information
The role of gene signatures in the prediction of therapeutic response to personalized therapies for lung cancer
John D. Minna, MD
Session 2b from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 14:47
Click Here For More Information
The prognosis and prediction of therapeutic response to personalized therapies for head & neck cancer
Edward S. Kim, MD
Session 2c from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 19:54
Click Here For More Information
ERCC-1 and RRM1: Survival-determining genes in lung cancer
George R. Simon, MD, FACP, FCCP
Session 2d from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 11:54
Click Here For More Information
Genomic predictors for clinical outcomes in resectable patients with lung cancer and head & neck cancer
David Jablons, MD
Session 2e from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 22:42
Click Here For More Information
Systems approach to personalized molecular medicine
Gordon Mills, MD, PhD
Session 2f from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 20:49
Click Here For More Information
Point-Counterpoint: All patients diagnosed with lung cancer should have their tumors profiled for genetic markers. Pro and Con. Audience Votes.
Joseph R. Nevins, PhD vs. David Jablons, MD
Session 2g from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 13:07
Click Here For More Information
Role of Biomarkers in Determining Sensitivity and Resistance to Anti-Microtubule Agents: Taxanes, Vincas, Epothilones
David R. Gandara, MD
Session 3a from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 17:58
Click Here For More Information
Biomarkers for platinum based therapies
George R. Simon, MD, FACP, FCCP
Session 3b from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 12:51
Click Here For More Information
Predicting clinical response to combination chemotherapy using histology for multi-targeted antifolates in sub-populations of non-small cell lung cancer
Ralph Zinner, MD
Session 3c from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 17:44
Click Here For More Information
Pharmacogenetic differences among lung cancer patient populations: implications for personalized therapy
Primo N. Lara, Jr., MD
Session 3d from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 13:25
Click Here For More Information
Personalizing the role of taxanes and platinum compounds for the treatment of head & neck cancer
Jeffrey N. Myers, MD, PhD
Session 3e from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 22:57
Click Here For More Information
What is the role of RRM1 as a molecular biomarker for predicting response to anti-metabolites?
Gerold Bepler, MD, PhD
Session 3f from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 18:00
Click Here For More Information
Point-Counterpoint: Tumor genetic mutations are critical for determining the choice of chemotherapy. Pro and Con. Audience Votes.
George R. Simon, MD, FACP, FCCP vs. Primo N. Lara, Jr., MD
Session 3g from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 17:23
Click Here For More Information
Case Study #1 and Q & A Interactive Panel Discussion: What are the State of the Art First- and Second-Line C hemo-Based Therapies? And what current and potential future biomarkers can be used to help clinicians devise personalized therapies? Audience response system handsets will be used to poll the participants.
Ravi Salgia, MD, PhD, audience, and this sessions faculty
Session 3h from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 22:52
Click Here For More Information
EGFR mutations and their role in predicting sensitivity and resistance to anti-EGFR therapy for lung cancer and head & neck cancer
Thomas J. Lynch, MD
Session 4a from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 16:36
Click Here For More Information
The role of FISH and IHC in predicting outcome to anti-EGFR therapy in lung and head & neck cancers
Fred R. Hirsch, MD
Session 4b from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 22:13
Click Here For More Information
The role of Kras mutation testing in lung cancer and head & neck cancer
Mark G. Kris, MD
Session 4c from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 18:11
Click Here For More Information
Mining the proteome for clinically useful signatures in lung cancer
David P. Carbone, MD, PhD
Session 4d from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 15:13
Click Here For More Information
Are molecular biomarkers effective predicting anti-EGFR therapies in combinations with novel agents directed against other targets and pathways?
Vincent A. Miller, MD
Session 4e from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 19:10
Click Here For More Information
Point-Counterpoint: EGFR small molecules versus EGFR antibodies: which are more valuable? Pro and Con. Audience Votes.
Vincent A. Miller, MD vs. Thomas J. Lynch, MD
Session 4f from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 14:38
Click Here For More Information
Personalizing the use of anti-VEGF monoclonal antibodies for the treatment of lung cancer and head & neck cancer
Alan B. Sandler, MD
Session 5a from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 14:44
Click Here For More Information
Personalizing the clinical applications of small molecule tyrosine kinase inhibitors for the treatment of lung cancer and head & neck cancer
Joan H. Schiller, MD
Session 5b from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 13:49
Click Here For More Information
Multiple-targeted tyrosine kinase inhibitors: can their usage be personalized for the treatment of lung cancer and head & neck cancer?
Thomas J. Lynch, MD
Session 5c from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 16:05
Click Here For More Information
The role of predictive molecular biomarkers in personalizing therapies targeting VEGF for lung cancer and head & neck cancer
John V. Heymach, MD, PhD
Session 5d from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 14:50
Click Here For More Information
Point-Counterpoint: The best targets for inhibiting angiogenesis in lung cancer are the VEGF receptor and ligand. Pro and Con. Audience Votes.
Alan B. Sandler, MD vs. John V. Heymach, MD, PhD
Session 5e from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 10:44
Click Here For More Information
Case Study #3 and Q & A Interactive Panel Discussion: What are the State of the Art First- and Second-Line Anti-Angiogenic-Based Therapies? And what current and potential future biomarkers can be used to help clinicians devise personalized therapies? Audience response system handsets will be used to poll the participants.
Jyoti D. Patel, MD, audience, and this sessions faculty
Session 5f from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 18:05
Click Here For More Information
Maturing role of EGFR Inhibition in LA-NSCLC
Corey J. Langer, MD
Session 6a from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 22:48
Click Here For More Information
Personalizing radiation therapy with anti-angiogenic agents
Walter J. Curran, MD, FACR
Session 6b from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 13:31
Click Here For More Information
Case Study #4 and Q & A Interactive Panel Discussion with Faculty and audience using the audience response system handsets
Faculty and Audience
Session 6c from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 12:44
Click Here For More Information
Examples of enrichment designs in lung cancer trials by the CALGB Respiratory Core
Everett E. Vokes, MD
Session 7a from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 13:59
Click Here For More Information
Personalizing therapies for lung cancer patients utilizing Cox-2 inhibitors
Martin J. Edelman, MD
Session 7b from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 14:50
Click Here For More Information
New targets: IGF-1R and mitotic spindle kinases
Paul A. Bunn, Jr., MD
Session 7c from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 26:32
Click Here For More Information
Is there a role for personalizing therapies for Small Cell Lung Cancer?
Alan B. Sandler, MD
Session 7d from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 08:08
Click Here For More Information
Antiemetics in 2008-2009: Targeting antiemetic agents and doses for appropriate patients
Richard J. Gralla, MD
Session 7e from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 20:58
Click Here For More Information
Predictive markers in head & neck cancer therapy
David Sidransky, MD
Session 7f from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 17:12
Click Here For More Information
Point-Counterpoint: The majority of therapies for treating lung cancer will be personalized with molecular biomarkers by the year 2015. Pro and Con.
Paul A. Bunn, Jr., MD vs. Richard J. Gralla, MD
Session 7g from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 26:26
Click Here For More Information
Case Study #5 and Q & A Interactive Panel Discussion: What are Some Emerging Therapies? And what current and potential future biomarkers can be used to help clinicians devise personalized therapies? Audience response system handsets will be used to poll the participants.
Philip Bonomi, MD, audience, and this sessions faculty
Session 7h from the First Annual North American Symposium on Personalized Therapies for Lung Cancer and Head & Neck Cancer
Date of release: November 15, 2008
Date expires: November 15, 2009
Duration: 13:18
Click Here For More Information
|
